Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors.

William L Dahut; Nehal J Lakhani; James L Gulley; Philip M Arlen; Elise C Kohn; Herbert Kotz; Debbie McNally; Allyson Parr; Diana Nguyen; Sherry X Yang

doi:10.4161/cbt.5.1.2349

Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors.

NobleID: NI9P51W62R26S94
Persistent link: https://nobleid.org/ark:/48914/w1/20260515/0B49A2CF

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/0B49A2CF.svg?ark=w1%2F20260515%2F0B49A2CF&value=id)](https://nobleid.org/work/w1/20260515/0B49A2CF)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors.

NobleID: NI9P51W62R26S94
Persistent link: https://nobleid.org/ark:/48914/w1/20260515/0B49A2CF

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/0B49A2CF.svg?ark=w1%2F20260515%2F0B49A2CF&value=id)](https://nobleid.org/work/w1/20260515/0B49A2CF)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work